key: cord-0780258-lb2ybn0b
authors: Tripathy, Satyajit; Dassarma, Barsha; Roy, Somenath; Chabalala, Hlupheka; Matsabisa, Motlalepula Gilbert
title: A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
date: 2020-05-22
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106028
sha: 8e68d96538d97f3b97f1f1fabd4fbf8369d9f6e1
doc_id: 780258
cord_uid: lb2ybn0b

The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries’ leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing.

(https://clinicaltrials.gov). Chloroquine has been found to act as an anti-tumour as well as an anticancer agent [8] and further indicating that chloroquine supplementation with conventional treatments on glioblastoma patients might improve the mid-term survival of these patients.

Another study has found that chloroquine diminishes intratumoural hypoxia [9] as a result making the cancer cell more sensitive for radiotherapy or other oxygen-dependent therapies [10] and for dominant metastasis. It is documented that autophagy promotes many cancers [11] .

Autophagy occurs in cells under several conditions. This degradative process forms auto phagosome that retains degraded cell components, which then fuse with lysosomes to be recycled. It is understood that autophagy is halted by chloroquine by disrupting the energy source of the autophagy pathway [12, 13] . Despite the inhibition of the autophagic flux of CQ and HCQ against cancer, another study has reported that these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer cells. In addition, in the tumour stroma, CQ affects the tumour vasculature, cancer-associated fibroblasts and the immune system [7] .

CQ has shown its wide-ranging properties against bacteria, fungal, protozoal, parasitic and viral infections. In a study, Newman et al [14] have shown that chloroquine boosts human macrophages to suppress the growth of yeast, by limiting the availability of iron in macrophage.

Chloroquine induced human mononuclear phagocytes kills the Cryptococcus neoformans, most commonly found in immune deficient patients [14, 16] . Besides such immune modulation by chloroquine, in a combination therapy against drug resistant Candida albicans, chloroquine has shown promising effects by inhibiting biofilm formation at low concentrations [17] .

Humans have been under threat due to an outbreak of the novel coronavirus disease (COVID-19;

previously known as 2019-nCoV) [18] which was first reported in Wuhan, China in late December 2019 [2] . Consequently, the virus infection has been declared a pandemic. As of 24 th April 2020, about 2 620 000 people have been reported as confirmed cases with COVID-19 and with over 181 000 deaths [1] . COVID-19 is an acute resolved disease which can be deadly if not immediately and properly managed. The severity of the disease is for massively causing alveolar damage, with respiratory failure and consequently death [2] . However, no pathology has been reported due to barely accessible autopsy or biopsy of affected patients [2] . Every country in the world is exhaustively trying to get a cure or preventative measures against this virus. At present, all treatments are symptomatic and supportive. Despite that anti-inflammatory and antiviral treatments have been employed, no specific antiviral drugs have been confirmed effective.

Given that the development of a vaccine is time dependent, physicians and scientists are trying to find quick but effective treatments for the COVID-19. Scientific information currently available suggests that reports of several clinical trials are suggesting that the age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Accumulating scientific reports have proposed and highlighted the possible different modes of actions of chloroquine/hydroxychloroquine, particularly, against viral infections.

Chloroquine (known as chloroquine phosphate), a 4-amino-quinoline, was introduced in 1945 as medicine against malaria. Hans Andersag and co-workers at the Bayer laboratories discovered it in 1934. It is a weak base drug and exists in protonated and unprotonated forms. Before it, quinine from cinchona tree bark was natural antimalarial agent. In 1891, Paul Ehrlich's group chemically synthesized CQ with methylene blue, a dye, which can kill malaria parasite selectively. Through the chemistry work and the structure activity relationships (SARS) by change of the basic methyl group, resulted in a more effective antimalarial agent, pamaquine.

Subsequently, the attachment of the basic side chain of pamaquine to several different heterocyclic ring systems resulted in the synthesis of an acridine derivative quinacrine, which has an extra benzene ring. Further research resulted in the discovery of two chloroquine analogues, sontoquine and primaquine, which were improved and better antimalarial drugs [19] . Studies on these compounds then lead to the discovery of resochin. During World War II, investigations on resochin lead to synthesis CQ. Hydroxychloroquine (HCQ) sulfate, a derivative of CQ, was first synthesized in 1946 by introducing a hydroxyl group into CQ and was demonstrated to be much less (~40%) toxic than CQ in animals [20, 4] (Fig 1) . It is also believed that HCQ has less blood retinal barrier permeability and is less toxic to retina than CQ [21, 22] .

The pharmacokinetic properties of hydroxychloroquine are almost similar to that of chloroquine, but it is reported that hydroxychloroquine is less active than chloroquine against resistant malaria parasite, leaving chloroquine as the only age-old drug against malaria until emergence of CQ-resistant malaria parasite. The solubility of the drug and/or its analogues in water and its absorption occurs almost entirely in the digestive tract. The plasma level of the drug or its analogues has been found to reach a peak 4-12h after initial dose. The half-live of chloroquine and hydroxychloroquine are long, ranging from between 40 to 50 days. Chloroquine analogs have strong affinities to blood constituents, highly protein bound, particularly thrombocytes and granulocytes, which reduces its plasma concentrations. In addition, a major fraction of the chloroquine analogs in plasma is bound to plasma proteins, primarily albumin [23, 24, 25] .

Since the last decades humans have been confronted with emerging and reemerging of several viruses like, dengue [26, 27, 28] , Ebola [29, 30] , Avian influenza, severe acute respiratory syndrome (SARS) [31, 32] , Middle east respiratory syndrome (MERS) [33] , hepatitis c, chikungunya (CHIKV) [34, 35] , human immune deficiency virus (HIV) [36, 37, 38, 39] and others. In vitro study revealed that CQ is effective at both entry, and at post entry stages of SARS-COV-2 infection in Vero E6 cells [40] .

Currently, for SARS-COV-2 virus which causes COVID-19, there are no specific therapeutic strategies available. Physicians, researchers and scientists are involved in several clinical trials of chloroquine and/or hydroxychloroquine at different stages (Table 1 ; Data source:ClinicalTrial.org) in search for a treatment to curb the menace of COVID-19 pandemic.

Chloroquine with its unprotonated form can easily diffuse across the cell membranes to acidic vesicles of cytoplasm (lysosomes, late endosomes, trans-Golgi network (TGN) vesicles) and is trapped in the vesicles after being protonated. The protonated chloroquine is unable to diffuse out from the lysosome or endosomes, the cellular compartments restrain with hydrolases. As chloroquine and/or its analogues is a diprotic weak base and its unprotonated form can selectively enter into the lysosomes, and become protonated in a manner inversely proportional to pH (according to the Henderson-Hasselbach law) [41, 42] ; and a reason they are known as lysomotropic agents [43] .

The hydrolases' optimal activity is maintained in the lysosomes and/or TGN with the help of H+-ATPase activity, which maintains pH 5.0 inside those compartments [44] . The H+-ATPase of lysosome influx H+ ions through ATP-dependent pumps, an irreversible drug accumulation rises inside the lysosome (Fig. 2) , from the cytoplasm because of the differences of pH. The drug alters the acidic environment in the lysosomes and as a result, the cell cannot proceed further with endocytosis, exsosome release and phagolysosomal fusion in systematically [45] . In addition, An et al. [46] have reported that CQ/HCQ can also hamper the interaction between cytosolic DNA and the nucleic acid sensor cyclic GMP-AMP (cGAMP) synthase (cGAS) when in the cytosol [47] The elevation of pH into the lysosomes by the interference of CQ or HCQ, obstructs the antigen presentation, chemotaxis, proteolysis by the cell. The reduction of antigen presentation due to the elevation of pH by CQ/HCQ, decreases the antigen-MHC complex, as auto antigenic peptides have low affinity for self-MHC. The reduced amount of self-peptide-MHC complex on antigen presenting (AP) cells consequence subordinate activity of other target cells as well as release of cytokines by immune cells like T-cells and other AP cells [48] .

Moreover, CQ/HCQ causes a sporadic obligation between toll-like receptor (TLR) 7 and TLR 9

and their RNA/DNA ligands, due to changing of pH towards the basic, in the cellular endosomal environment, which suppressed TLR signaling [49, 50, 47] . The impending of STING pathway (TLR and cGAS response of interferon genes) results in the attenuation of pro-inflammatory cytokines like, TNF, IL6, IL1 (Fig 3) [51, 47] On the other hand, enveloped viruses are trapped within the endoplasmic and TGN vesicles for post-translational modification of its envelope glycoproteins. This process involves proteases and glycosyl-transferases, some of which require a low pH environment. By neutralizing the acidic pH, CQ/HCQ becomes responsible for the deactivation of several enzymes in the vesicles, like, glycosylating enzymes, glycosyltransferases, which in turn are responsible for the inhibition of glycosylation. The inhibition of glycosylation results in the host developing adaptive immune response against the infection [52, 48] and impair the cellular receptor of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-1 and blocks the fusion with the host cell [53, 22] . In connection, it is believed that SARS-CoV-2 also employ ACE2 receptor to enter the host cell [54, 53, 55] . Colson et al [55] , have reported that, the spike protein of SARS-COV-2 is cleaved into the autophagosome, formed by inhibition of cathepsins because of the changing of pH in lysosome as a result of CQ accumulation.

In addition, several studies showed that many human viruses, like influenza [56] , corona virus [57, 58] , which affects the respiratory tract; enter into the cell with the help of sialic acid linked gangliosides [59] . Including sialic acid receptor [58] , angiotensin converting enzyme receptor 2 (ACE2) [60] , transmembrane serine protease 2 (TMPRSS2) [61, 62] , and extracellular matrix metalloproteinase inducer (CD147, also known as basigin) [63] are under investigation of the researcher about the entry of such sever acute respiratory syndrome corona viruses into the human cell (Fig. 4) .

biosynthesis through inhibiting quinine reductase-2. The viruses use the sialic acid moieties as receptors [23] . Considering the higher transmissibility of SARS-CoV-2, Fantini et al., [64] have observed that on cell surface attachment factor, sialic-acid-containing glycoproteins and gangliosides, by molecular modeling study. The results support that CQ and HCQ bind readily to sialic acids with high affinity [58] , also bind to sialic-acid containing gangliosides [64] . [69] . In another study, Gautret et al. [70] reported that, at day 6 post-inclusion, 70% of patients were cured with 600 mg hydroxychloroquine (200 mg, 3 times daily for 10 days) compared to 12.5% with patients in the control group (p=0.001).

Recently, two trials in China NCT04261517 (HCQ: 400mg/day, 5 days) and

ChiCTR2000029559 (HCQ: 200mg BD) have released their findings. Based on context details from a clinical trial of China (ChiCTR2000029741) (14) , 50% efficacy of chloroquine phosphate (five days drugs) was observed in COVID-19 compared to 20% efficacy from lopinavir / ritonavir combinatorial (five days drugs) in Chinese patients with pneumonia [71] . Huang et al. [72] found in clinical study that chloroquine-treated patients (500 mg orally, 10 days twice daily) are better off than patients treated with lopinavir / ritonavir. Consequently, chloroquine-treated patients have already been released from the hospital. Another clinical trial, conducted with hundred chinese patients with COVID 19 infection, reported that CQ phosphate had remarkable result both in terms of clinical outcome and viral clearance comparing to control group [73] . The Gao et al. [73] also reported that the drug 'was effective in inhibiting the exacerbation of pneumonia, improving lung imaging, a virus-negative and shortening the activity against COVID-19 infection. They recommended the drug for adding in guidelines for the prevention, diagnosis, and treatment of pneumonia caused by COVID-19' [74] .

There are some preliminary non-peer reviewed scientific reports now coming out which suggest that CQ/HCQ may not beneficial for use in COVID 19. Another study report from Brazil warns that the high-dose group patients had more severe QT prolongation (syndrome of heart rhythm disorder, causes arrhythmias) and tendency near higher lethality compared to the low dose. At the time of their reporting, the overall fatality rate across both arms of the study was 13.5%.

They are indicating that the percentage of fatality rate was overlapping with the patients, not taking CQ [75] . Medical Centres, where a total of 368 patients were followed. In this study, patients were groups into those that received hydroxychloroquine alone (HCQ) or HCQ with azithromycin (HCQ+AZ) as treatments in addition to a group that received no treatment but standard supportive management for Covid-19. The analysis looked at two primary outcomes, which were death and the need for mechanical ventilation. The authors of this study concluded that they found no evidence of the efficacy of HCQ alone or in combination with AZ. They found that mortality was higher in patients receiving HCQ alone (27.8 %) and in combination of HCQ+AZ (22.1%) while significantly lower in the group receiving no drug treatment (11.4%) [77] .

According to the authors they found association of mortality in patients treated with HCQ alone.

Although these studies are small and retrospective, they highlight important decision making to not rush into widespread recommendation of these drugs for COVID-19.

Considering the global health crisis for the COVID-19 pandemic, the option of using the drugs, chloroquine and hydroxychloroquine, especially, hydroxychloroquine drug, in the treatment of SARS-CoV-2 might be the logical approach to follow. With the available of scientific information, the reports point to the diverse mode of actions of CQ and/or HCQ, that puts them as favorable choice for COVID-19 on their effect for both pre and post viral infections, but of course we need to put attention on doses as well negative effect of CQ/HCQ on human health. However, with new evidence coming out, there is need for precautionary measure to be taken not to rush in recommending the CQ/HCQ for use for COVID-19 patients. We need to wait for results that would come out of larger prospective, randomized, dose determining controlled clinical trials before making clinical recommendations for HCQ and indicating it for COVID-19.

In the meantime, while looking for a vaccine, which may be preventative, in-depth but expedited responsive discovery and clinical research is needed and this include looking at traditional medicines-based research therapies. 

Novel coronavirus (2019-nCoV) situation reports

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival

Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells

Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. E-cancermedicalscience

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double blind, placebo-controlled trial. Annals of internal medicine

Chloroquine anticancer activity is mediated by autophagy-independent effects on the tumor vasculature. Molecular & cellular oncology

Chloroquine engages the immune system to eradicate irradiated breast tumors in mice

The roles of autophagy in cancer

Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer research

Autophagy: shaping the tumor microenvironment and therapeutic response. Trends in molecular medicine

Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. The Journal of clinical investigation

Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation

Adjunctive immune therapy for fungal infections. Clinical infectious diseases

Chloroquine sensitizes biofilms of Candida albicans to antifungal azoles. The Brazilian Journal of Infectious Diseases

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine

Development of antimalarial drugs and their application in China: a historical review. Infectious diseases of poverty

Antimalarials in dermatology: mechanism of action, indications, and side effects

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries

Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrobial agents and chemotherapy

Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine

Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection

Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells

Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiology and immunology

Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and biophysical research communications

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Chikungunya fever--expanded distribution of a re-emerging tropical infectious disease

Chikungunya virus: an update on antiviral development and challenges. Drug discovery today

Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine

Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for Tcell activation

Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins

Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research

Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Chloroquine transport via the malaria parasite's chloroquine resistance transporter

Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function

Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications

Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacology research & perspectives

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. The Journal of Immunology

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virusinfected patients. Nature medicine

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Host lipid rafts play a major role in binding and endocytosis of influenza A virus

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Structural basis for human coronavirus attachment to sialic acid receptors

Sialic acid receptors of viruses

Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. The Journal of infectious diseases

Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery

In Vitro Antiviral Activity and Projection of Optimized Dosing All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease

Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review

Treating COVID-19 with chloroquine

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized

The authors express gratitude to the Department of Pharmacology University of the Free State,